The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset
of type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Gerstein, Hertzel, MD
Collaborators:
Aventis Pharmaceuticals Canadian Institutes of Health Research (CIHR) GlaxoSmithKline King Pharmaceuticals is now a wholly owned subsidiary of Pfizer Wyeth is now a wholly owned subsidiary of Pfizer